In recent years, the advent of targeted therapies for estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 positive (HER2+) breast cancers has significantly improved outcomes for breast cancer patients. Here, ERBB2 is linked to breast carcinoma.